Treatment of bacterial dysentery
First Claim
1. A compound of the following structure:
-
space="preserve" listing-type="equation">MFC-(LA).sub.n -(BM).sub.nwherein;
MFC is a multifunctional core molecule,LA is a linker arm,BM is a bridging molecule which includes two or more di-or tri-saccharides, and which can optionally include large oligosaccharides,n is, independently, between 3 and 20,the di- or tri-saccharide moiety are optionally linked to between one and eight additional saccharide moieties, and include an individual saccharide moiety selected from the group consisting of α
Gal(1→
4)β
Gal, α
Gal(1→
4)β
Gal(1→
4)β
GlcNAc, and α
Gal(1→
4)β
Gal(1→
4)β
Glc,the bridging moieties are bound to at least one linker arm,the linker arms are, independently, C6-20 straight, branched or cyclic alkanes, in which one or more of the carbons may optionally be replaced with an O, S, or amine, and the linker arms can optionally be functionalized at one or more positions with a functional group selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic,and pharmaceutically acceptable salts thereof.
1 Assignment
0 Petitions
Accused Products
Abstract
Compounds which bind to shiga-like toxins (SLT) associated with enteric E. coli infection, compositions including the compounds, methods for the neutralization of (SLT) in a patient, and methods for the diagnosis of enteric E. coli infection are disclosed. The compounds include a core molecule bound to a plurality of linker arms, which in turn are bound to a plurality of bridging moieties, which in turn are bound to two or three di- or tri-saccharide moieties. The di- or tri-saccharide moieties themselves are active in binding to the SLTs. The presence of a plurality of bridged dimers of the di- and tri-saccharides is responsible for the increased binding affinity of the compounds relative to the di- and tri-saccharides themselves. The compounds, when administered in a timely fashion to a patient suffering from enteric E. coli infection, inhibit progression of this infection into hemolytic uremic syndrome (HUS).
30 Citations
19 Claims
-
1. A compound of the following structure:
-
space="preserve" listing-type="equation">MFC-(LA).sub.n -(BM).sub.nwherein; MFC is a multifunctional core molecule, LA is a linker arm, BM is a bridging molecule which includes two or more di-or tri-saccharides, and which can optionally include large oligosaccharides, n is, independently, between 3 and 20, the di- or tri-saccharide moiety are optionally linked to between one and eight additional saccharide moieties, and include an individual saccharide moiety selected from the group consisting of α
Gal(1→
4)β
Gal, α
Gal(1→
4)β
Gal(1→
4)β
GlcNAc, and α
Gal(1→
4)β
Gal(1→
4)β
Glc,the bridging moieties are bound to at least one linker arm, the linker arms are, independently, C6-20 straight, branched or cyclic alkanes, in which one or more of the carbons may optionally be replaced with an O, S, or amine, and the linker arms can optionally be functionalized at one or more positions with a functional group selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, and pharmaceutically acceptable salts thereof. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)
-
Specification